Table 1.
Compound | IC50 (µg/mL) a | ||||
---|---|---|---|---|---|
A549 | SMMC-7721 | EJ | Hela | BALL-1 | |
1 | 6.70 ± 1.05 | 5.17 ± 0.97 | 31.93 ± 2.84 | 17.82 ± 2.34 | 11.15 ± 1.62 |
2 | 31.67 ± 2.36 | 35.62 ± 2.73 | 47.45 ± 3.22 | 70.61 ± 3.95 | 33.91 ± 2.78 |
3 | >100 | >100 | >100 | >100 | 94.88 ± 3.25 |
4 | 17.04 ± 0.58 | >100 | 30.59 ± 2.73 | >100 | 22.54 ± 2.03 |
5 | 7.30 ± 0.46 | 9.09 ± 0.51 | 38.18 ± 2.23 | 46.63 ± 2.62 | 12.50 ± 1.47 |
6–8 | >100 | >100 | >100 | >100 | >100 |
DOX b | 3.53 ± 0.25 | 1.35 ± 0.28 | 5.88 ± 0.18 | 2.11 ± 0.21 | 6.99 ± 0.37 |
a Inhibitory activity was expressed as the mean ± SD of 50% inhibitory concentration of triplicate determinations and was obtained by interpolation of concentration-inhibition curve. b Doxorubicin (positive control).